Baxter Likorall Overhead Lift Recall Z-0151-2027 Recall

Baxter Healthcare Corporation recalled Likorall overhead lifts under FDA recall number Z-0151-2027, a Class II device recall the FDA classified on October 13, 2026. The FDA’s stated reason is a potential issue involving motor shaft breakage combined with reduced performance of the Single Fault Safety (SFS) system, which may cause the lift strap to lower more quickly than expected during use. The recall is voluntary and firm initiated, and the FDA lists its status as Ongoing. Patients face some risk of injury if a significant fall or drop were to occur from this issue.

At a glance

• The recalling firm is Baxter Healthcare Corporation of Deerfield, Illinois, at 1 Baxter Pkwy, 60015-4625.
• The FDA classified recall Z-0151-2027 as Class II on October 13, 2026, and the openFDA record lists its status as Ongoing.
• The recall was initiated on September 14, 2026, and the FDA published its report date as October 21, 2026.
• Baxter described the action as voluntary and firm initiated, with an initial firm notification by letter.
• Distribution was US nationwide across every state the FDA listed plus pending international distribution.

What does the Baxter Likorall recall cover?

Recall Z-0151-2027 covers Likorall overhead lift models spanning several product codes. The product description lists the LIKORALL 200 (product code 3121001) and multiple 242 ES, 242 S, 243 ES, 250 ES, 250 S and 250 S IRC configurations, with natural and white color variants and R2R variants. Product codes are identifiers the FDA uses to group devices of the same kind.

The FDA record ties affected units to serial number intervals or minimum serial numbers by model, not to a single shared range. For the LIKORALL 200, the listed intervals are 8400054 to 8450499 and 9000000 to 9000999. Other models list thresholds such as “greater than or equal to” a starting serial number, or closed intervals, with a separate UDI-DI number per product code. A UDI-DI is the device identifier portion of a unique device identification code.

What is established vs. what is alleged

The recall entry is the FDA’s classification record of an action the firm carried out, not a finding by a court. The following points are established in that record:

• Baxter initiated the recall on September 14, 2026, on a voluntary basis.
• The FDA assigned Class II and classified the action on October 13, 2026.
• The FDA reports the reason as a potential motor shaft breakage issue combined with reduced SFS performance that may allow the lift strap to lower faster than expected.
• The firm’s stated concern is injury risk if a significant fall or drop occurs.

The record does not establish that any patient was injured, that any specific unit failed, or that a defect has been proven in any individual lift. The reason statement uses the word “potential,” and the injury language is conditional, framed as a risk if a significant fall or drop were to occur. A Class II designation reflects the FDA’s severity categorization of the recall, not a judicial finding against the firm.

Where the recall stands procedurally

There is no federal court consolidation tied to this recall in the supplied record. The claims and events described here sit in the FDA’s regulatory process, not in multidistrict litigation. An MDL, or multidistrict litigation, is a procedure that centralizes related federal lawsuits before one judge for pretrial proceedings; no MDL number appears anywhere in the source documents for this recall. No bellwether trial, which is a test case chosen from a group of similar lawsuits, is identified here, and the Judicial Panel on Multidistrict Litigation (JPML), the body that decides whether to consolidate federal cases, is not referenced in the record for this matter.

The regulatory posture is an open, ongoing Class II recall. The FDA’s recall database explains that a record’s create date reflects when the FDA classified the recall, not necessarily when the action began, and that status is updated when the FDA identifies a violation and classifies the action and again when the recall is terminated. As of the October 21, 2026 report date, the openFDA entry lists the recall as Ongoing, meaning the FDA has not recorded termination.

For comparison, device litigation that does reach federal court follows a separate path. Other device matters on this site, such as the Bard implanted port catheter litigation and the Philips CPAP ventilator recall litigation, illustrate how product liability claims can proceed alongside or after a recall. Those pages describe different products and do not involve the Baxter Likorall lifts.

Key dates

• September 14, 2026: Baxter Healthcare Corporation initiated the Likorall overhead lift recall.
• October 13, 2026: the FDA classified the action as Class II under recall number Z-0151-2027.
• October 21, 2026: the FDA report date for the recall, with the openFDA record listing status as Ongoing.
• October 21, 2026: the openFDA device enforcement dataset was last updated.

What this does not establish

The record does not establish that the SFS system failed on any specific lift, or that motor shaft breakage has occurred in any unit in the field. It does not state how many units are affected; the product quantity field in the FDA entry is blank. It does not identify any injury, lawsuit, settlement, verdict or court ruling connected to the recall. It does not establish that Baxter admitted liability or wrongdoing. It does not describe the content of the notification letter beyond the FDA’s note that the initial firm notification was by letter. It also does not address whether the recall has been terminated or completed, since the status remains Ongoing.

Frequently asked questions

What is the Baxter Likorall overhead lift recall?

The Baxter Healthcare Corporation Likorall overhead lift recall is FDA recall number Z-0151-2027, a Class II device recall the FDA classified on October 13, 2026. Baxter initiated the action voluntarily on September 14, 2026. The FDA lists the reason as a potential motor shaft breakage issue combined with reduced Single Fault Safety system performance that may allow the lift strap to lower faster than expected.

Which Likorall models are included in recall Z-0151-2027?

The recall covers Likorall overhead lift models including the LIKORALL 200 under product code 3121001 and multiple 242, 243 and 250 series configurations. Affected units are identified by serial number intervals or minimum serial numbers listed by product code in the FDA entry. Each product code carries its own UDI-DI number.

Did the FDA report any injuries in this recall?

The FDA record for recall Z-0151-2027 does not report any injury. Its reason statement describes a potential issue and says patients are at some risk of injury if a significant fall or drop were to occur. The record describes a risk, not a confirmed harm.

Is there a lawsuit or MDL for the Baxter Likorall recall?

No court consolidation appears in the supplied record for recall Z-0151-2027. The action is a voluntary FDA-classified device recall with status listed as Ongoing. No MDL number, trial date or court ruling is identified in the source documents.

Sources

1. U.S. Food and Drug Administration (openFDA): “Device Enforcement Report, recall number Z-0151-2027” (link, accessed 2026-11-01)
2. U.S. Food and Drug Administration: “510(k) Premarket Notification Database” (link, accessed 2026-11-01)
3. U.S. Food and Drug Administration: “Medical Device Recalls Database” (link, accessed 2026-11-01)
4. U.S. Food and Drug Administration (openFDA): “Device Enforcement Report, default query” (link, accessed 2026-11-01)
5. U.S. Food and Drug Administration (openFDA): “510(k) Premarket Notification data, default query” (link, accessed 2026-11-01)
6. U.S. Food and Drug Administration: “Medical Devices” (link, accessed 2026-11-01)
7. U.S. Food and Drug Administration: “Device Advice: Comprehensive Regulatory Assistance” (link, accessed 2026-11-01)